Andy Trotti

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Patient-reported outcomes and the evolution of adverse event reporting in oncology
    Andy Trotti
    Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
    J Clin Oncol 25:5121-7. 2007
  2. ncbi request reprint Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512)
    Andy Trotti
    Department of Radiation Oncology, University of South Florida H Lee Moffittt Cancer Center, Tampa, Florida Electronic address
    Int J Radiat Oncol Biol Phys 89:958-63. 2014
  3. pmc Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4727-32. 2009
  4. doi request reprint Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Am J Otolaryngol 30:38-43. 2009
  5. ncbi request reprint TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
    Lancet Oncol 8:613-24. 2007
  6. pmc Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1351-5. 2008
  7. ncbi request reprint A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 58:674-81. 2004
  8. ncbi request reprint Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation
    Yuhchyau Chen
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 64:1442-51. 2006
  9. ncbi request reprint Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Radiother Oncol 66:253-62. 2003
  10. ncbi request reprint CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
    Semin Radiat Oncol 13:176-81. 2003

Detail Information

Publications19

  1. ncbi request reprint Patient-reported outcomes and the evolution of adverse event reporting in oncology
    Andy Trotti
    Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
    J Clin Oncol 25:5121-7. 2007
    ..Therefore, care must be used when developing health outcomes and safety data collection plans...
  2. ncbi request reprint Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord (RTOG 9512)
    Andy Trotti
    Department of Radiation Oncology, University of South Florida H Lee Moffittt Cancer Center, Tampa, Florida Electronic address
    Int J Radiat Oncol Biol Phys 89:958-63. 2014
    ..To compare hyperfractionation versus standard fractionation for T2N0 vocal cord carcinoma in a randomized controlled trial...
  3. pmc Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4727-32. 2009
    ....
  4. doi request reprint Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Am J Otolaryngol 30:38-43. 2009
    ..Squamous cell carcinoma (SCC) is associated with IP in about 7% of cases. To date, there has been no pooled analysis to formulate a survival outcome associated with this rare condition...
  5. ncbi request reprint TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
    Lancet Oncol 8:613-24. 2007
    ....
  6. pmc Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1351-5. 2008
    ..This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma...
  7. ncbi request reprint A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 58:674-81. 2004
    ..It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM...
  8. ncbi request reprint Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation
    Yuhchyau Chen
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 64:1442-51. 2006
    ....
  9. ncbi request reprint Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Radiother Oncol 66:253-62. 2003
    ..To determine the frequency of mucositis and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer through a systematic review of recently published literature...
  10. ncbi request reprint CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
    Semin Radiat Oncol 13:176-81. 2003
    ..This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0...
  11. doi request reprint Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma
    Tawee Tanvetyanon
    Head and Neck Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Arch Otolaryngol Head Neck Surg 135:687-92. 2009
    ..To investigate the potential value of postoperative concurrent chemoradiation among patients with high-risk salivary gland carcinomas...
  12. pmc Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305 5847, USA
    J Clin Oncol 27:4281-6. 2009
    ..To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial...
  13. ncbi request reprint Assessment of toxicity in cooperative oncology clinical trials: the long and short of it
    Clement K Gwede
    Dept of Interdisciplinary Oncology, University of South Florida and H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
    J Oncol Manag 11:15-21. 2002
    ..The potential implications for toxicity data management practices, data quality, patient care management and resource utilization are discussed...
  14. ncbi request reprint The evolution and application of toxicity criteria
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
    Semin Radiat Oncol 12:1-3. 2002
    ..Just as the revised CTC has provided a new common standard for the grading of acute effects, a similar effort is needed in the late effects area. The creation of a unified late effects system is under active development...
  15. pmc Evaluation of new treatments in radiation oncology: are they better than standard treatments?
    Heloisa P Soares
    H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
    JAMA 293:970-8. 2005
    ..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
  16. ncbi request reprint The need for adverse effects reporting standards in oncology clinical trials
    Andy Trotti
    J Clin Oncol 22:19-22. 2004
  17. ncbi request reprint Complications of radiation therapy for head and neck cancers. The patient's perspective
    Alison M Rose-Ped
    Empirica, Inc, Portland, Ore 97225, USA
    Cancer Nurs 25:461-7; quiz 468-9. 2002
    ..Trends toward more aggressive management of head and neck cancers underscore the need for new and effective therapies for oropharyngeal mucositis occurring in patients receiving radiotherapy...
  18. ncbi request reprint Measurement of quality of life in head and neck cancer patients utilizing the quality of life radiation therapy questionnaire
    Monika Janda
    Department of Radiotherapy and Radiobiology, University Hospital Medical School of Vienna, Austria
    Strahlenther Onkol 178:153-8. 2002
    ..We aimed to translate the radiation specific quality of life questionnaire (QOL-RTI) and the companion head and neck module (H&N) questionnaire into German and to test its reliability, validity and sensitivity...
  19. ncbi request reprint Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14
    K Kian Ang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
    J Clin Oncol 23:3008-15. 2005
    ..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...